Empery Asset Management, LP
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$81.4M2026 Q3+ $15.1M options (notional, not included)
Positions34
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.88.4%
What Changed This Quarter?
Top Holdings
XFOR
X4 Pharmaceuticals
29.2%
EMPD
Empery Digital
15.1%
ModernaPUT
Moderna
14.6%
OTLK
Outlook Therapeutics
12.6%
NGEN
Nervgen Pharma
6.5%
Zone Frontier
Zone Frontier
2.7%
PYXS
Pyxis Oncology
2.4%
CLRB
Cellectar Biosciences
1.8%
New / Increased
10 new · 4 increased
ModernaPUTNEW
Moderna
14.6%
OTLKNEW
Outlook Therapeutics
12.6%
Zone FrontierNEW
Zone Frontier
2.7%
PYXSNEW
Pyxis Oncology
2.4%
AMLXNEW
Amylyx Pharmaceuticals
1.8%
XFOR
X4 Pharmaceuticals
29.2%
+40.3%
EMPD
Empery Digital
15.1%
+64.8%
CLRB
Cellectar Biosciences
1.8%
+403.7%
Reduced / Exited
9 reduced · 8 sold out
DTIL
Precision Biosciences
0.7%
-86.8%
CLNN
Clene
0.9%
-75.8%
NGEN
Nervgen Pharma
6.5%
-17.3%
TNYA
Tenaya Therapeutics
1.3%
-44.9%
One And One G…
One and One
0.5%
-59.0%
ANVSEXIT
Annovis Bio
5.2%
AMCEXIT
Amc Entmt
3.8%
VenuEXIT
Venu
1.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.